A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.
Beylot-Barry, Marie
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. [electronic resource] - The Journal of investigative dermatology 09 2018 - 1982-1989 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1523-1747
10.1016/j.jid.2018.03.1516 doi
Aged
Aged, 80 and over
Biopsy
Disease-Free Survival
Dose-Response Relationship, Drug
Female
France--epidemiology
Humans
Immunologic Factors--administration & dosage
Leg
Lenalidomide--administration & dosage
Lymphoma, Large B-Cell, Diffuse--drug therapy
Male
Neoplasm Recurrence, Local
Remission Induction
Skin--pathology
Skin Neoplasms--drug therapy
Survival Rate--trends
Treatment Outcome
A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. [electronic resource] - The Journal of investigative dermatology 09 2018 - 1982-1989 p. digital
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1523-1747
10.1016/j.jid.2018.03.1516 doi
Aged
Aged, 80 and over
Biopsy
Disease-Free Survival
Dose-Response Relationship, Drug
Female
France--epidemiology
Humans
Immunologic Factors--administration & dosage
Leg
Lenalidomide--administration & dosage
Lymphoma, Large B-Cell, Diffuse--drug therapy
Male
Neoplasm Recurrence, Local
Remission Induction
Skin--pathology
Skin Neoplasms--drug therapy
Survival Rate--trends
Treatment Outcome